» Articles » PMID: 25240411

Interventional Pulmonologist Perspective: Treatment of Malignant Pleural Effusion

Overview
Specialty Oncology
Date 2014 Sep 22
PMID 25240411
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The management of known malignant pleural effusions focuses around the initial thoracentesis and subsequent objective and subjective findings. A completely reexpanded lung after fluid removal and with symptomatic improvement predicts successful pleurodesis. Pleurodesis method depends on center expertise as well as patient preference. Medical thoracoscopy does not require the operating room setting and is performed on the spontaneously breathing patient with similar success rate to surgical thoracoscopy in the appropriately selected patients. However, it is not widely available. Talc insufflation is preferred for even distribution of sprayed particles to pleural surfaces. Most often, patients can be discharged home within 24 to 48 hours after continuous chest tube suction. Indwelling pleural catheter has become popular given the ease of insertion and patient centered home drainage. Coordinated care with good patient and family education and support is paramount to maximizing the beneficial potential of the catheter. Complications are minimal, and catheters are easily removed if patients can no longer benefit from drainage, or if pleurodesis has occurred. In the setting of trapped lung as a result of visceral pleura encasement from tumor, indwelling catheter can still be useful if the patient improves with thoracentesis. However, if no subjective improvement is seen after thoracentesis for trapped lung, then no procedure is recommended and other modes of palliation should be sought.

Citing Articles

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.

Tao H, Meng Q, Li M, Shi L, Tang J, Liu Z Thorac Cancer. 2018; 9(2):298-304.

PMID: 29297985 PMC: 5792722. DOI: 10.1111/1759-7714.12582.


Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion.

Moon Y, Kim K, Park J J Cardiothorac Surg. 2015; 10:136.

PMID: 26510956 PMC: 4625971. DOI: 10.1186/s13019-015-0340-8.

References
1.
Hunt I, Teh E, Southon R, Treasure T . Using non-steroidal anti-inflammatory drugs (NSAIDs) following pleurodesis. Interact Cardiovasc Thorac Surg. 2007; 6(1):102-4. DOI: 10.1510/icvts.2006.140400. View

2.
Harris R, Kavuru M, Rice T, KIRBY T . The diagnostic and therapeutic utility of thoracoscopy. A review. Chest. 1995; 108(3):828-41. DOI: 10.1378/chest.108.3.828. View

3.
Hsu L, Soong T, Feng A, Liu M . Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. J Thorac Oncol. 2007; 1(5):460-7. View

4.
Barbetakis N, Asteriou C, Papadopoulou F, Samanidis G, Paliouras D, Kleontas A . Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg. 2010; 5:27. PMC: 2873359. DOI: 10.1186/1749-8090-5-27. View

5.
Gasparri R, Leo F, Veronesi G, De Pas T, DePas T, Colleoni M . Video-assisted management of malignant pleural effusion in breast carcinoma. Cancer. 2005; 106(2):271-6. DOI: 10.1002/cncr.21623. View